Although interfering with NF-κB addiction in ABC DLBCL is appealing, its pleiotropic nature may jeopardize the success of its targeting and urges us to establish treatments that selectively kill tumor cells while sparing healthy cells. This evidence concerns the gene NFKB1 and diffuse large B-cell lymphoma.